Risk-benefit stratification as a guide to lidocaine prophylaxis of primary ventricular fibrillation in acute myocardial infarction: an analytic review
- PMID: 392960
- PMCID: PMC2595788
Risk-benefit stratification as a guide to lidocaine prophylaxis of primary ventricular fibrillation in acute myocardial infarction: an analytic review
Abstract
Early investigators suggested that ventricular fibrillation without heart failure in acute myocardial infarction was reliably preceded by warning arrhythmias, and that suppression of such arrhythmias with intravenous lidocaine could avoid the need for resuscitation. While the efficacy and safety of lidocaine have been substantiated, the reliability of warning arrhythmias as predictors for primary ventricular fibrillation has not. We present data showing that the risk of primary ventricular fibrillation is most dependent on the patient's age and the interval since the onset of his symptoms, rather than on the presence of warning arrhythmias. We have estimated that lidocaine prophylaxis would have to be given to about 12 patients in the highest risk group (patients under age 50 and within six hours of the onset of symptoms), compared to about 400 patients in the lowest risk group (patients above age 70 and more than 24 hours since the onset of symptoms), to prevent one episode of primary ventricular fibrillation in each group. We propose that these risk stratifications, as adapted to the conditions in specific hospitals, provide the most rational approach to lidocaine prophylaxis of primary ventricular fibrillation.
Similar articles
-
Lidocaine prophylaxis for fatal ventricular arrhythmias after acute myocardial infarction.Clin Pharmacol Ther. 1995 Apr;57(4):471-8. doi: 10.1016/0009-9236(95)90218-X. Clin Pharmacol Ther. 1995. PMID: 7712677 Clinical Trial.
-
[Prognostic significance of arrhythmias in acute myocardial infarction (author's transl)].Z Kardiol. 1977 Jun;66(6):267-72. Z Kardiol. 1977. PMID: 331707 Review. German.
-
Lidocaine prophylaxis in acute myocardial infarction.Henry Ford Hosp Med J. 1991;39(3-4):217-25. Henry Ford Hosp Med J. 1991. PMID: 1804827 Review.
-
Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction.N Engl J Med. 1985 Oct 31;313(18):1105-10. doi: 10.1056/NEJM198510313131801. N Engl J Med. 1985. PMID: 3900727 Clinical Trial.
-
Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine.Am J Cardiol. 2004 Sep 1;94(5):545-51. doi: 10.1016/j.amjcard.2004.05.014. Am J Cardiol. 2004. PMID: 15342281
Cited by
-
The pharmacokinetics of lignocaine and beta-adrenoceptor antagonists in patients with acute myocardial infarction.Clin Pharmacokinet. 1987 Nov;13(5):293-316. doi: 10.2165/00003088-198713050-00002. Clin Pharmacokinet. 1987. PMID: 2891461 Review.
-
Antiarrhythmic prophylaxis after acute myocardial infarction. Is lidocaine still useful?Drugs. 1993 Jan;45(1):9-14. doi: 10.2165/00003495-199345010-00002. Drugs. 1993. PMID: 7680988 Review. No abstract available.
-
Exploring the relationship between ventricular fibrillation recurrence after defibrillation in myocardial infarction and the effectiveness of renal sympathetic denervation therapy.BMC Cardiovasc Disord. 2024 Oct 29;24(1):604. doi: 10.1186/s12872-024-04222-1. BMC Cardiovasc Disord. 2024. PMID: 39472838 Free PMC article.
-
Effects of cardiovascular disease on pharmacokinetics.Cardiovasc Drugs Ther. 1989 Oct;3(5):711-30. doi: 10.1007/BF01857622. Cardiovasc Drugs Ther. 1989. PMID: 2577313 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources